Page 12 - Oncocyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oncocyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oncocyte Today - Breaking & Trending Today
Equities research analysts at StockNews.com began coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a research report issued on Sunday. The firm set a “sell” rating on the stock. OncoCyte Price Performance About OncoCyte (Get Rating) OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of […] ....
Equities research analysts at StockNews.com started coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a report released on Sunday. The brokerage set a “sell” rating on the stock. OncoCyte Stock Performance OncoCyte Company Profile (Get Rating) OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of […] ....
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research report released on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC lowered their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a […] ....
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report published on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC cut their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a report […] ....
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research note released on Thursday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price target on OncoCyte from $1.40 to $0.45 and set a buy rating for the company in a research note on […] ....